CIK 0000949858 · Non-accelerated filer<br>Smaller reporting company
ACHIEVE LIFE SCIENCES, INC.
Sign in to watch- Ticker
- ACHV
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 954343413
- Phone
- 425-686-1500
- Business address
- 22722 29TH DR. SE, SUITE 100, SEATTLE, WA, 98021
- Former names
- ONCOGENEX PHARMACEUTICALS, INC., SONUS PHARMACEUTICALS INC
- SC 13G Stake Amended Statement of Ownership
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- EFFECT Other Notice of Effectiveness
- CORRESP Other Correspondence Between Filers and SEC Staff
- UPLOAD Other SEC-generated Letter
- S-3 Offering Registration Statement
- ARS Other Annual Report to Security Holders
- DEF 14A Proxy Proxy Statement
- 4 Shares withheld for taxes Principal Accounting Officer gave up 2,250 shares (to pay taxes)
- 4 Shares withheld for taxes President & CMO gave up 3,957 shares (to pay taxes)
- 4 Shares withheld for taxes Executive Chairman gave up 10,125 shares (to pay taxes)
- 4 Shares withheld for taxes CEO gave up 6,088 shares (to pay taxes)
- S-8 Other Securities Offered to Employees in Benefit Plans
- 10-K Report Annual Report
- 8-K Event Results of operations
- SC 13G Stake Amended Statement of Ownership
- 4 Open-market buy Executive Chairman bought 10,000 shares at $4.59 ($45,850)
- 4 Open-market buy CEO bought 10,000 shares at $4.59 ($45,850)
- 8-K Event Material agreement · Agreement ended · Results of operations · Unregistered share sale · Regulation FD disclosure
Page 9 of 68 · 1,358 filings